ICDDR,B LIBRARY **DHAKA - 12**

Application No. 16-032 (Cevised) Application No. 16-03 (Cevised) Application No. 16-032 (Cevised) Applica		TARRETTEE, TEPOR.B. \$ 12/0701
Supporting Agency (if Non-ICDDR, B) WHO OF NUTRIENTS IN PRESTRINT DIARRHOGA OPHASE I Trule the appropriate answer to each of the following (If Not Applicable write NA). Source of Population: (a) 111 subjects (b) Non-111 subjects (c) Minors or persons under guardianship Doos the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks to subjects (d) Piscomfort to subjects yes (d) Ploscomfort to subjects yes (d) Ploscomfort to subjects (e) Invasion, of privacy (f) Disclosure of information tion damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of fetal tissue or followed including alternatives used (c) Physical risks (c) Physical risks (d) Sensitive questions (e) Discomfort to be derived (c) Should be included in the abstract summer of study (e) No (d) Sensitive questions (es) No (e) Completed including alternatives used (es) No (e) Completed including alternatives used (es) No (f) Right to rofuse to participate or to with-draw from study (g) Confidential handling of data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (g) Confidential handling or data (h) Compensation \$/or treatment where there are risks or privacy is involved in No (h) Compe	Principal investigator DR.S.K.Royl .	Traince Investigator (16 and)
OF MUTCHENTS IN PERSISTENT DIARRHOEA . C PHASE I Trois the appropriate answer to each of the following (If Not Applicable write NA). Source of Population: (a) Ill subjects (b) Non-ill subjects (c) Minors or persons under guardianship Doua the study involve: (a) Physical risks to the subjects (b) Social-Risks (c) Psychological risks to subjects (d) Piscomfort to subjects 'ves (No) (e) Invasion of privacy peace or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Proceedures to be followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Right to refuse to participate or to with- draw from study (g) Confidential handling of data (h) Compensation 8/or treat- ment where there are risks or privacy is implayed in	Application No. 86-033 (Roviced)	
DIARCHOEA . CPHASE I Incide the appropriate answer to each of the following (If Not Applicable write MA). Source of Population: (a) Ill subjects (b) Non-Ill subjects (c) Minora or persons under guardianship (e) No (a) Physical risks to the subjects (c) Psychological risks (c) Psychological risks (d) Piscomfort to subjects (e) Invasion of privacy (f) Discolosure of information damaging to subject or others (c) Use of organs or body (c) Use of forgans or body (d) Disco fetal tissue or abortus (e) Physical risks (f) Use of forgans or body (g) Consistive questions (h) Use of fetal tissue or abortus (d) Psychological pisks (e) Psychological risks (f) Discolosure of information damaging to subject or others (h) Use of forgans or body (c) Use of organs or body (d) Discomfort to subject or others (e) Use of organs or body (f) Discolosure of information damaging to subject or others (h) Use of forgans or body (f) Discolosure of the following (If Not Applicable write MA). (a) Natural precautions be taken to project annoymity of subjects are minors) (ves) No (ii) procedures be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects (ves) No (iii) precautions be taken to project annoymity of subjects (ves) No (iii) precautions be taken to project annoymity of subjects (ves) No (iii) precautions be taken to project annoymity of subjects (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subjects are minors) (ves) No (iii) precautions be taken to project annoymity of subje	ith of Study INTAKE Q AGGOTION	
Ircle the appropriate answer to each of the following (If Not Applicable write MA). Source of Population: (a) Ill subjects (b) Non-Ill subjects (c) Minors or persons under guardianship Dood the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks (d) Piscomfort to subjects Yes (No) (e) Invasion of privacy (f) Disclosure of information damaging to subject or others Does the study involve: (a) Use of organs or body Illuds Are subjects (c) No Objects (c) No Objects (c) No Objects (c) Invasion of privacy (d) Use of organs or body Illuds Are subjects (c) No Objects (c) Invasion of privacy Objects (c)	ACALISTO CALLED AND ACALISTON	
No change (do not fill out rest of form)	OF MUTRIENTS IN PERSISTENT	
Ircle the appropriate answer to each of the following (If Not Applicable write NA). Source of Population: (a) 111 subjects (b) Non-111 subjects (c) Minors or persons under guardianship Dous the study involve: (a) Physical risks to the subjects (c) Psychological risks to subjects (e) Invasion of privacy (f) Discomfort to subjects (e) Invasion of privacy (f) Discovere of information damaging to subject or others Does the study involve: (a) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) No (f) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) No (g) Confidential handling of data (h) Compensation \$/or treat ment where there are risks or privacy is involved in (a) From subjects (a) From subjects (a) From subjects (b) From parent or guardian (if subjects are minors)(Yes) No (Will precautions be taken to profect anonymity of subjects are minors)(Yes) No (Will precautions be taken to profect anonymity of subjects are minors)(Yes) No (Will precautions be taken to profect anonymity of subjects are minors)(Yes) No (Will precautions be taken to profect anonymity of subjects are minors)(Yes) No (Described risks to the subjects are minors)(Yes) No (Will precautions be taken to profect anonymity of subjects are minors)(Yes) No (Described risks to the subjects are minors)(Yes) No (Check documents being submitted hirriwith to (Dispersation to subjects or nature of study, risks, types of questions to be asked, and right to refuse to participate or withdray (Required) Informed consent form for subjects or nature of study, risks, types of questions to be asked, and right to refuse to participate or withdray (Required) Informed consent form for parent or nature of study, risks, types of questions to be asked, and right to refuse to participate or withdray (Required) Informed consent form for parent or inte	DIARRHOEA CPHASE I)	t / Continuation with change
(a) From subjects (b) Non-Ill subjects (c) Minors or persons under guardianship (cf) Minors or persons under guardianship (cf) Moode the study involve: (a) Physical risks to the subjects (cf) Physical risks to the subjects (cf) Physical risks to the subjects (cf) Physical risks (cf) P		No change (do not fill out rest of form)
(a) From subjects (b) Non-Ill subjects (c) Minors or persons under guardianship (cf) Minors or persons under guardianship (cf) Moode the study involve: (a) Physical risks to the subjects (cf) Physical risks to the subjects (cf) Physical risks to the subjects (cf) Physical risks (cf) P	Source of Persiants answer to each of	of the following (If Not Applicable write May
(c) Non-Ill subjects (c) Minors or persons under guardianship Doos the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks to subjects (d) Piscomfort to subjects ves (d) Piscomfort to subjects ves (e) Invasion of privacy (f) Disclosure of information damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Arm subjects clearly informed about: (a) Nature and purposes of (c) Physical risks (d) Sensitive questions (e) Prom subjects are minors) Yes No (if subjects are minors) Yes No (c) Check documents being submitted herewith to Committee: (mbrella proposal - Initially submit overview (all other requirements will be submitted with individual studies; Protocol (Required) Statement give or read to subjects on nature of study, risks, types of questions to be asked, and right to refuse to participate or withdraw (Required) Informed consent form for subjects Informed consent form for parent or guardian Frocedure for withdraw (Required) Ves No (a) Use of retal tissue or abortus (b) Use of organs or body fluids Arm subjects Yes (c) Use of organs or body fluids Arm subjects Yes (d) No (e) Informed consent form for subjects Informed consent form for subjects Informed consent form for parent or guardian Frocedure with individual studies; Protocol (Required) Statement give with individual studies; Protocol (Required) Nature of study, risks, types of questions to be asked, and right to refuse to participate or withdraw (Required) Informed consent form for subjects Interview which could be considered with individual studies; Protocol (Required) Nature of study, risks, types of questions to r	(B) Ill subject	- " * * * * * * * * * * * * * * * * * *
(c) Minors or persons under guardianship Doos the study involve: (a) Physical risks to the subjects (b) Social Risks (c) Psychological risks to subjects (d) Piscomfort to subjects Yes (e) Invasion of privacy (f) Disclosure of Information damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of (b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived Yes No (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of dats (h) Compensation \$/or treatment with recoverient for parent or guardian (if subjects are minors) Yes No (c) Mill precautions be taken to profect anonymity of subjects are minory its obligates with individual studies; Protocol (Required) Statement given or read to subjects to participate or withdraw (Required) Statement given or read to subjects to participate or withdraw (Required) Statement given or read to subjects to participate or withdraw (Required) Statement given or read to subjects to participate or withdraw (Required) Informed consent form for parent or guardian (if subjects are minors) Yes No (Committee: Umbrella proposal - Initially submit to overview (all other requirements will be submitted herewith to overview (all other requirements will be submitted herewith to overview (all other requirements will be submitted herewith to overview (all other requirements will be submitted herewith to overview (all other requirements will be submitted herewith to overview (all other requirements will be submitted herewith to overview (all other requirements will to everview (all other requirements will to everview (all other requirements will be submitted herewith to overview (all other requirements will to everview (all other requirements will to everview (all other requirement	(b) Non-111 authors	(a) From subjects
under guardianship Dous the study involve: (a) Physical risks to the subjects (Psychological risks to subjects (b) Social-Risks (Psychological risks to subjects (Psychological risks (Psycho		(b) From parent or guardian
(a) Physical risks to the subjects (Psychological risks (Psychological r	under guardianshin	(1) Subjects are minoral Year No.
(a) Physical risks to the subjects (Psychological risks (Psychological r	. Dogs the study involve:	o. all precautions be taken to protect
Subjects (b) Social Risks (c) Psychological risks to subjects (d) Piscomfort to subjects (e) Invasion of privacy (f) Disclosure of information damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of riddy (b) Procedures to he followed including alternatives used (c) Physical risks (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Physical risks (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Committee: Umbrella proposal - Initially submit overview (all other requirements will be submitted with individual studies). Protocol (Required) Abstract Summary (Required) Statement given or read to subjects on nature of study, risks, types of questions to be asked, and right to refuse to participate or withdraw (Required) Informed consent form for subjects Informed consent form for parent or guardian Frocedure for maintaining confidential ity Questionnaire or interview schedule If the final instrument is not completed prior to review, the following information should be included in the abstract summar: A description of the areas to be covered in the questionnaire or interview which could be considered cither sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. An indication as to when the questionnaire will be presented to the Cttree. for review.	(a) Physical risks to the	anonymity of subjects was no
(c) Psychological risks to subjects (d) Piscoafort to subjects (e) Invasion of privacy (e) Invasion of privacy	subjects yes (M	Committee to Committee description of Committee description of Committee description of the Committee d
to subjects (d) Pisconfort to subjects Yes (d) Disclosure of information damaging to subject or others (et al., medical, death, birth or other) (b) Use of fetal tissue or abortus (et al., medical, death, birth or other) (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of (et al., medical) Procedure for maintaining confidential indy (b) Procedures to he followed including alternatives used (et al., medical) Procedure for maintaining confidential indy (c) Procedures to he followed including alternatives used (et al., medical) Procedure for maintaining confidential indy (d) Sensitive questions Yes (d) Sensitive questions Yes (d) Sensitive questions Yes (d) Sensitive questions Yes (d) Sensitive forms to be derived (f) Right to refuse to participate or to withdraw (result of the final instrument is not completed prior to review, the following information should be considered cither sensitive or which would constitute an invasion of privacy. (e) Benefits to be derived (f) No (final final	(D) Social Risks	~ · · · · · · · · · · · · · · · · · · ·
(d) Procedures to he followed including alternatives used (e) Physical risks (e) No (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Cospensation \$for trest ment where there are risks or privacy is inspired as to ment where there are risks or privacy is inspired as to ment where there are risks or privacy is inspired as to ment where there are risks or privacy is inspired as to make the submitted with individual studies?	(c) Psychological risks	OHOLETIM DIOPOSBI - INITIALIO CUPALA
(e) Invasion of privacy (f) Disclosure of information damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body (fluids Aro subjects clearly informed about: (a) Nature and purposes of followed including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Benefits to be derived (res) No (g) Confidential handling of data (h) Compensation \$/or treatment where there are risks or privacy is involved in No	to subjects yes fi	be submitted with individual mill
(f) Disclosure of information damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (res) No participate or to withdray (Required) (e) Physical risks (f) Right to refuse to participate or interview schedule constitute an invasion of privacy. (g) Confidential handling of data (h) Compensation \$/or treat ment where there are risks or privacy is involved in the sinuspace of the Ctree. Astatement given or read to subjects on nature of study, risks, types of questions to be asked, and right to refuse to participate or withdray (Required) Informed consent form for subjects to participate or body Informed consent form for parent or auardian Procedure for maintaining confidential interview schedule consolided in the abstract summary of the final instrument is not completed prior to review, the following information should be considered either sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctree. for review.	TO SUDJECTS IN A	2. Protocol (Required)
tion damaging to subject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of iddy (b) Procedures to he followed including alternatives used (c) Physical risks (c) Benefits to be derived (res) No participate or to with-draw (res) No	THE DESCRIPTION OF THE PROPERTY OF THE PROPERT	AUSTRACE SUBMERY (Peruland)
ject or others Does the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (d) Nature and purposes of indy (e) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (res) No participate or to withdray (Required) (e) Benefits to be derived (res) No participate or to withdray (Required) (f) Right to refuse to participate or to withdray (Required) (g) Confidential handling of data (h) Compensation \$/or treatment is not completed prior to review, the following information should be included in the abstract summary interview which could be considered cither sensitive or which would constitute an invasion of privacy. 2. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctrue. for review.	The second of th	Statement given or read to subjects as
lose the study involve: (a) Use of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of heldy (b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Benefits to be derived (F) No participate or to withdraw (Required) Informed consent form for subjects Informed consent form for parent or guardian Frocedure for maintaining confidential ity Questionnaire or interview schedule. (a) Nature and purposes of the final instrument is not completed prior to review, the following information should be included in the abstract summary and escription of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. (e) Confidential handling of data (h) Compensation 6/or treatment where there are risks or privacy is involved in held of the Cttree in the presented to the Cttree for review.	1 m m m m m m m m m m m m m m m m m m m	INTUITE OF STUDY, PISKS, types of angu-
Ilse of records, (hospital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of holy followed including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Benefits to be derived (res) No participate or to withdraw (Required) Informed consent form for subjects Informed consent form for parent or guardian Frocedure for maintaining confidential ity (Questionnaire or interview schedule in the final instrument is not completed prior to review, the following information should be included in the abstract summer: A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Cttree for review.	Does the study involve:	7 " 1985 to be asked, and right to require
ital, medical, death, birth or other) (b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of birth or including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treatment is not completed prior to review, the following information should be considered either sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctree. for review.	(a) Use of records (bosn	Purticipate or withdraw (Required)
birth or other) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of body followed including alternatives used (b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treatment is not completed prior to review, the following information should be included in the abstract summary and description of the areas to be covered in the questionnaire or interview which could be considered cither sensitive or which would constitute an invasion of privacy. 2. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Cttree for review.	ital, medical, death	Intorage consent for subjects
(b) Use of fetal tissue or abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of body followed including alternatives used (c) Physical risks (d) Sensitive questions (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in the approach to the constitute an invasion of privacy. (a) No (b) Procedures to he following information should be included in the abstract summar: (b) Procedures to he following information should be considered covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. (e) Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctree. (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in	birth or other) (van un	informed consent form for parent or
abortus (c) Use of organs or body fluids Are subjects clearly informed about: (a) Nature and purposes of beginning alternatives used (b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived Yes No (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in No (c) Use of organs or body fluids (d) No (res) No (e) No (e) No (f) Right to refuse to participate or to with-draw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in No (g) Use of organs or body fluids (f) No (g) No (g) No (es) No (es) No (es) No (es) No (f) Right to refuse to participate or to with-draw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in No (h) No (res) No (ity (Questionnaire or interview schedule for review. (ity (Questionnaire or interview schedule for review, the following information schould in the abstract summary interview which could be considered cither sensitive or which would constitute an invasion of privacy. (it) A description of the areas to be covered in the questionnaire or interview which could be considered cither sensitive or which would constitute an invasion of privacy. (it) A description of the areas to be covered in the questions to be asked in the sensitive areas. (it) A description of the areas to be covered in the questions of the type of specific questions to be asked in the sensitive areas. (it) A description of the areas to be covered in the question of the covered in the privacy of the type of specific questions to be asked in the sensitive areas. (it) A description of the included in the sensitive areas	(b) Use of fetal tissue or	guardian
fluids Are subjects clearly informed about: (a) Nature and purposes of high results in the following information of the abstract summary of high results in the following information of the abstract summary in the followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat near where there are risks or privacy is involved in high results in the final instrument is not completed prior to review, the following information should in the abstract summary in the following information should in the abstract summary is highly desired in the description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. 2. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctree. for review.	abortus yes No	rocedure for maintaining confidential
(a) Nature and purposes of ridy (b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (es) No participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat- ment where there are risks or privacy is involved in houter interview, the following information should in the abstract summar: A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Ctree. for review.	Use of organs or body	
(a) Nature and purposes of help have to review, the following information should be included in the abstract summary of the following information should be included in the abstract summary of the following information should be included in the abstract summary of the following information should be considered for the questionnaire or interview which could be considered for either sensitive or which would constitute an invasion of privacy. 2. Examples of the type of specific questions to be asked in the sensitive areas. 3. An indication as to when the questionnaire will be presented to the Cttree. for review.	fluids (Yes) No	If the final material schedule
(b) Procedures to he followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (res) No participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat ment where there are risks should be included in the abstract summar; A description of the areas to be covered in the questionnaire or interview which could be considered either sensitive or which would constitute an invasion of privacy. Examples of the type of specific questions to be asked in the sensitive areas. An indication as to when the questionnaire will be presented to the Ctree. for review.	subjects clearly informed about:	Trior to review the following terms
(c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat- ment where there are risks or privacy is involved in	(w) Hature and purposes of	Should be included in the observer
followed including alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (ves No (f) Right to refuse to participate or to with- draw from study (g) Confidential handling of data (h) Compensation \$/or treat- ment where there are risks or privacy is involved in		A description of the areas
alternatives used (c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat ment where there are risks or privacy is involved in	20 10	covered in the questionnairs or
(c) Physical risks (d) Sensitive questions (e) Benefits to be derived (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in	alternatives and	interview which could be considered
(d) Sensitive questions (e) Benefits to be derived (ves) No (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat-ment where there are risks or privacy is involved in No.	(C) Physical mast	
(c) Benefits to be derived (Yes) No (f) Right to refuse to participate or to withdraw from study (g) Confidential handling of data (h) Compensation \$/or treat- ment where there are risks or privacy is involved in No	(d) Sanaistus austa	constitute an invasion of privacy
(f) Right to refuse to participate or to with- draw from study (8) Confidential handling of data (h) Compensation 4/or treat- ment where there are risks or privacy is involved in	(o) Benefits to be derived (vac)	/ Examples of the type of specific
participate or to with- draw from study (8) Confidential handling of data (h) Compensation \$\forall \text{rest}^{\text{Yes}} \text{No} (n) Compensation \$\forall \text{rest}^{\text{Yes}} \text{No} (n) Compensation \$\forall \text{rest}^{\text{Yes}} \text{No} (n) The state of the confidence of the	(f) Right to refuse to	questions to be asked in the sensitive
(g) Confidential handling of data (h) Compensation 6/or treat— ment where there are risks or privacy is involved in	participate or to with-	areas.
(8) Confidential handling of data (h) Compensation 6/or treat— ment where there are risks or privacy is involved in	draw from study (es) No	on indication as to when the question-
(h) Compensation \$/or treat— ment where there are risks or privacy is involved in	(8) Confidential handling	maire will be presented to the Ctree.
ment where there are risks or privacy is involved in	of data Yes No	TAL TRAIRS.
or privacy is involved in \rangle \rangle \rangle	The state of the s	
any pertended and NA	or reises to the risks	
	any perticular necessary in N	A .

dgree to obtain approved of the Ethical Review Committee for any changes olving the rights and welfare of subjects before making such change.

OCT 29 <u>1986</u>

Principal lawestigator

Traince

(PTO)

R888n 1986

86-033(Revised)

SECTION 1 - RESEARCH PROTOCOL

DEFINED DIETS IN PERSISTENT DIARRHOEA

2. PRINCIPAL INVESTIGATOR: Dr. S.K. Roy 🕆

CO-INVESTIGATORS: Dr. R. Haider, A.N. Alam, and Dr. F.C. Patra

CONSULTANT: Prof. R. Eeckels, Dr. A.M. Molla

(PHASE I)

COLLAB. INVESTIGATOR: Prof. M.S. Akbar, Dhaka Shishu Hospital

3. STARTING DATE: October 1986.

4. COMPLETION DATE: September 1987

5. TOTAL DIRECT COST: US \$ 32,540

(POSSIBLE SOURCE OF FUNDING)

MHO

6. SCIENTIFIC DIVISION: This protocol has been approved by the

Head, Clinical Sciences Division

Signature of the Acting Head, Clinical Sciences Division

21.9.46.

7. ABSTRACT SUMMARY:

Persistent diarrhoea is directly responsible for growth faltering, malnutrition and mortality in children. The cornerstone of successful management of this critical syndrome lies on adequate nutrient absorption by the gastrointestinal tract. Selection of dietary ingredients depends upon exact knowledge of absorption during persistent diarrhoea. For the above purpose. 48 children with persistent diarrhoea will be studied in the metabolic ward of ICDDR,B. Exact amount of nutrient intake and absorption will be measured from familiar diet of defined composition. rehydration, charcoal marker will be fed; followed by the diet offered at lests of absorption for dietary carbohydrate, fat and protein will be performed and coefficient of absorption of the nutrient will be calculated. There will be 2 groups of children, each having a different diet during diarrhoea. A control group of children will be matched for age, sex and nutrition from the hospitalized nondiarrhoeal patients in Dhaka Shishu Hospital.

Comparison of absorption coefficients and other variables among diet groups and controls and their determinants also will be looked for.

Available data will be used for formulation of appropriate therapeutic diets for better management of persistent diarrheoa.

8. REVIEWS:

- (a) Ethical Review Committee: ------
- (b) Research Review Committee: -----
- (c) Director, ICDDR,B; ------

SECTION II - RESEARCH PLAN

A. INTRODUCTION:

1. Objective.

To estimate net intake and nutrient absorption in persistent diarrhoea using metabolic balance techniques in phase I to be followed by study of pathophysiology in phase II by the next protocol.

2. Background.

Though acute diarrhoea is a major health problem in many developing countries, there maybe hope now for its successful management mainly because of implementation of knowledge obtained from extensive works during the past decades. Persistent diarrhoea is a life threatening challenge to growth and child survival in both developed and countries, mostly due to inadequate understanding of its pathophysiology and nutrient utilization by the gastrointestinal tract. Although from irritable bowel syndrome to rare inborn errors of metabolism all types of long continued diarrhoea may fall under the term 'chronic diarrhoea', a vast majority of persistent diarrhoea in children with failure to begin with an acute episode of gastroenteritis. Though a definition still to be agreed upon, a duration of diarrhoea for at least 3 weeks will be acceptable as persistent diarrhoea (Merson MH, 1986). The negative impact of diarrhoea on growth and nutrition is now well documented but this effect is probably more deleterious during persistent diarrhoes. have been suggestions to define the persistent diarrhoea of acute infective origin as 'persistent postenteritis diarrhoea syndrome in children,

(Sack RB, 1984). The basis of the problem lies in the fact that nutrient absorption is impaired leading to malnutri-tion which in turn affects physiological process of digestion, absorption and metabolism, entering into a vicious cycle. This over simplification of the fact is far from the complex underlying derangements but besides further understanding of this process it is mandatory to formulate some therapeutic and dietary intervention for control of diarrhoea.

Magnitude of the problem

Although prevalence of persistent diarrhoea is lower than that of acute diarrhoea, significant impact of persistent diarrhoea on subsequent malnutrition and mortality has been identified quite early and is being more recognised now. A number of indepth studies have been reported from the developed parts of the world (Avery et al., 1968, Cohlan et al., 1956). On the otherhand several epidemiological studies from developing countries have indicated higher prevalence of persistent diarrhoea in those parts of the world than that of developed ones. It is not unlikely that 5-20% of children suffering from acute gastroenteritis may go on to persistent diarrhoea (Black et al., 1982, Snyder JD et al., 1982).

The persistent diarrhoea of infective origin must be dealt separately from other specific chronic diarrhoea syndromes such as, tropical sprue, tropical enteropathies, intractable and chronic non-specific diarrhoea of infancy, coeliac disease, inflammatory bowel diseases, blind loop syndrome, post surgical syndrome and necrotizing enterocolitis.

Although the complete understanding is far from clear, a considerable amount of information on persistent diarrhoea is now available from both developed and developing countries (Gordon JE, 1971, Gracey M, 1972). The

fact becomes clearer that there are significant differences in aetiology of persistent diarrhoea observed in different geographical and socioeconomic settings. In studies from London (Larcher, 1977), carbohydrate intolerance and milk protein intolerance were shown to be common cause of persistent diarrhoea in children below two years. Reports from Ethiopia, Bangladesh, and Guatemala showed that 4-7% of acute diarrhoeal patients became chronic (Gordon et al., 1968, Black et al., 1982, Mata et al., 1976). From surveillance studies on diarrhoeal diseases in two separate communities in Bangladesh, it has been reported that dysenteric type of illnesses continued to be persistent diarrhoea (Bari et al., 1986) and repeated attacks of acute diarrhoeal episodes lead to persistent diarrhoea (Rahman MM et al., 1986).

Prevalence of carbohydrate malabsorption causing persistent diarrhoea is Malabsorption of lactose was found in 12% of reported to be common. children in U.K. (Larchar et al., 1977), 31% in Australia (Halliday et al., 1982) 22% in Peru (Perez Flores 1972) and 80% in India (Ansari Z et al., 1979). Malabsorption of sucrose is also reported in chronic diarrhoea (Davidson et al., 1982, Chandra RK et al., 1968, Ansari Z et al., 1979). Several studies reported secondary monosaccharide intolerance in persistent diarrhoea (Kilby AM, 1977, Gracey M et al., 1969). Malabsorption of glucose has been successfully managed by replacing glucose with fructose in the diet ' (Lifshitz 1970, Jalili et al., 1982, Kilby AM, 1977). It can be mentioned that mild degrees of glucose malabsorption may occur in Rotavirus diarrhoea (Sack et al., 1982). Milk protein intolerance has been found in persistent diarrhoea where lactose intolerance might be associated (Lui et al. 1968). B lactoglobulin, fraction of milk protein has been postulated to be the cause of enteropathy, which now has been well recognized (Walker Smith JA, 1978). Similarly, soya protein intolerance is a recognized entity in childre. 'hitington et al., 1977).

During acute or persistent diarrhoea, there is significant change in mucosal permeability which is more severe in persistent diarrhoea (Ford RPK et al., 1985). It has been seen that antigenic protein uptake is increased during this state while cow's milk protein uptake causes to enteropathy and intolerance (Jackson D et al., 1983). Severe protein loss during diarrhoea can lead to persistent diarrhoea while endogenus protein from serum is reflected by — antitrypsin in stool. Molla et al have found very low co-efficient of absorption for dietary protein probably because of not taking account of endogenus protein loss from increased mucosal permeability, mucosal damage and bacterial protein in stool.

It has been demonstrated in a number of studies that small intestinal mucosal structure and enzymatic function vary significantly between wel-nourished and malnourished children (Chandra RK et al.,1968, Alleyene GAD et al., 1977). Pancreatic enzyme activity also varies according to nutritional status (Jain MK et al., 2986). Further studies on abnormal bacterial overgrowth in small intestine has been reported with significant difference between welnourished and severely malnourished children (Mehta AP et al., 1986). The above phenomena most likely further reduce digestion and absorption during persistent diarrhoea. A comparison of nutrient absorption during persistent diarrhoea with that in absence of diarrhoea needs to be controlled for nutritional status of the children.

Inability of nutrient digestion and absorption by the gastrointestinal tract per se, may be interrelated with several other
intermediate factors. Early supplementation with formula feeds, complex
carbohydrates of plant origin, excess undigestable cellulose, and
contaminated food continue to be common ingredients for feeding young
infants in developing countries.

Although several studies from different parts of the world have reported carbohydrate malabsoroption in persistent diarrhoea, there is no available information on quantitative and qualitative estimates of nutrient intake and utilization in persistent diarrhoea. Such report from Bangladesh is totally lacking and the only insight in this aspect has been studied in ICDDR,B in acute diarrhoea recently (Molla A et al., 1982, Sarker SA et al., 1982). It becomes evident from the information available that, depending on the extent and degree of pathophysiological derangement, gastrointestinal tract fails to handle dietary ingredients leading to a condition of persistent diarrhoea and malnutrition.

To understand this particular aspect we propose to undertake a balance study in young children with persistent diarrhoea to estimate nutrient intake and absorption in the ICDDR, B metabolic ward from defined familiar diets. Control value will be estimated in the similar way from matched non diarrhoeal children admitted to Dhaka Shishu Hospital in a collaborative study.

3. Rationale

A vast majority of malnourished children with persistent diarrhoea need dietary intervention which is still not welunderstood. Bangladesh is highly endemic for diarrhoea and persistent diarrhoea is a threatful challenge to health workers, it thus appears to be an area of priority. The study will be a pioneer one to exactly quantitate nutrient utilization in chronic diarrhoea and will enable to formulate dietary intervention to control persistent diarrhoea. Formulation of appropriate diet will reduce malabsorption and prevent subsequent risk of mortality from persistent diarrhoea.

B. SPECIFIC AIMS

- 1. To quantitate nutrient and energy intake in children during persistent diarrhoea and to assess the impact of specific diets on the stool output and duration of diarrhoea.
- 2. To estimate fat, carbohydrate and protein absorption during persistent diarrhoea from defined diet.
- 3. To carryout the above tests in an age, sex and nutrition matched control group of children without diarrhoea for purpose of comparison.

C. METHODS AND PROCEDURE

Selection_of_study_children

Male children of 3-24 months of age, having diarrhoea with acute onset (excluding bloody mucoid stool) for more than 21 days (PPDC), will be eligible. Those with a component of growth faltering (less than 80% wt. for age compared to NCHS standard) will be selected. Informed consent will be obtained from the legal guardian before recruiting for the study.

INVESTIGATIONS

Investigations will be done after obtaining the full clinical, feeding and socioeconomic information as follows:

- Measurement of nutritional status using recumbent length, body weight, age and mid arm circumference.
- Stool N.E. with formal ether concentration method for identification of <u>Giardia lamblia</u>, Sudan III stain for fat and modified Zehl Neelson stain for cryptosporidium.
- Stool culture for <u>E.coli</u>, ST, LT, EPEC, enterobacteriace,
 <u>Saleonella</u>, <u>Shigella</u>, and Cholera.

- ELISA for rotavirus

antitrypsin clearance in stool. (Radial Immunodiffusion method)

- Stool thin layer chromatography for sugar qualitative and quantitative
- Stool pH and glucose
- Permeability test (described briefly in appendix)
- D-Xylose absorption test (" " ')

Urine Routine analysis and culture

Blood CBE, platelet, electrolytes and culture if indicated

X-ray chest AP view if indicated

Balance Study

Study diet will be selected according to the scheme outlined in the page 13 which is presently used in ICDDR,8 for management of persistent diarrhoea. Patients will be put on study diet 2 days before the balance study. Ist marker will be given as charcoal tablet to be followed by study diet. A 2nd marker will be given after 48 hours at the same time of 1st marker. Time of appearance of 1st marker in stool will be taken as 0 hour. Collection of stool and urine will be started with the appearance of 1st marker untill second marker comes out. 5 ml of acetic acid will be given in the collecting buckets. Forty-eight hours dietary intake will be measured and recorded. All vomitus will also be collected in the same way. These samples will be kept in deep freeze at -20 C.

lst #a ker

2nd marker

e.g., at 10 a.m. on 21/5

marker out

collection started

10 a.m. on 23/5

2nd marker out

48 hr collection

stopped.

all marker stool will be saved.

Aliquots of stool samples from homogenized 48 hours collection will be taken and will be analysed for fat (by Vandekamer's method), nitrogen by Microkjheldal method (Henry RJ, 1964) and carbohydrate by subtracting those from total energy. Total energy will be determined by adiabetic Bomb Calorimetry. Dietary contents for fat, carbohydrate and protein will also be analysed. Total daily urinary nitrogen excretion will be estimated. Absorption will be estimated by substracting loss in stool from intake.

intake-loss X 100
Absorption co-efficient = ----intake
0.75

Gross energy intake per \(\) kg (metabolic intake) will be calculated to overcome the effect of body size on intake. Absorption per metabolic body size will also be calculated to assess exact utilization of nutrients.

Dietary_management

The child's usual home diet will be given till changes are made on dietary regimen on the basis of investigations. Two dietary groups will be made from the existing defined diets in current practice for managment of persistent diarrhoea in ICDDR, B. Rice suzi diet has been used with success in ICDDR, B and comminuted chicken is used in London and other places.

Die	ets to be used: 	Compositi	on/liter	diet selection
ı.	Milk, soya and sucr	ose free diet		
	Rice suzi:		•	Cow's milk protein,
	Rice powder Egg	60	•	Lactose and sucrose
	Oil	30	g	intolerance > > 4 months age
	Glucose	20 70/100	•	>6 months age in presence
2.	Milk, soya, sucrose complex carbohydrat	and	я 1	of grade III PEM
	Comminuted chicken:			•
	Minced chicken	- 180	g	Severe PEM with intrac-
	Glucose	. 25	g	table diarrhoea
	Oil	20	g	Failure with rice suzi
	Kc1	ı	g	(4 months age
	Papaya	20	g	
	Kcal	60/100	m l	

Indication for

After recovery from diarrhoea, transition home-diet will be given as test feeds. Based on the results of the balance study, investigations and clinical response dietary changes may be made.

Management_of_cases

Rehydration will be done with I.V. fluid or ORS and 8 hourly intake and output measures will be taken. Vital signs will be checked every 8 hours while study physicians care for 24 hours will be ensured. Appropriate infection control and regular assessment on improvement of diarrhoea will be monitored as shown in appendix.

Safety_of_the_study_children_and_exclusion

Any child developing sepsis, convulsion, enterocolitis, or any other lifethreatening condition will be immediately transferred to the intensive care unit and will be excluded from the study.

STATISTICAL CALCULATION:

Sample_size

Assuming the hypothesis that nutrient absorption will be at least 80 percent and unchanged in healthy children, which maybe reduced 25% in acute diarrhoea (Molla A, 1982). There may be at least equal reduction in persistant diarrhoea. A difference of 20% can be expected to be malabsorbed in children with persistent diarrhoea.

As there is no exact information on standard deviation of nutrient malabsorption in chronic diarrhoea an estimate can be assumed from data on acute diarrhoea (Molla A et al., 1982).

2 X S X 7.9 Using formula
$$\underline{n} \geq -----$$
 with 95% confidence limit d^2

(taking care of sensitivity or type 1 error) and with power 80%, number in each group becomes 16. For 3 group 12 treatment and 1 control 16 % 3 = 43 cases will be required for this study.

Variables:

- 1. Age, nutritional status
- Previous home feed
- Nutrient/Energy intake
- Absorption co-efficient:
 (a) Carbohydrate
 (2) fat
 (3) protein (total nitrogen)
- 5. Days required for recovery
- Xylose absorption
- 7. Stool volume

Analysis_of_data

Data generated from the study will be entered into micro computer and appropriate tests will be selected. Analysis of variance for comparibility, cross tabulations, Chi-squared test, or Student's 't' test as required, Mann Whitene U test, Wilcoxson's rank sum/sign test for comparison, and Regression analysis will be considered.

D. SIGNIFICANCE:

This study has been proposed to increase understanding of nutrient absorption (quantitative and qualitative) in chronic diarrhoea which will help to develop better care in this vulnerable group of patients. This body of knowledge will be of special help to those concerned with pediatric nutrition and feeding programmes.

E. FACILITIES REQUIRED:

- 1. Office space: The existing office space will be utilized.
- 2. Laboratory space: The existing lab. space will be utilized.
- 3. Hospital beds: Present metabolic ward with 2 beds will be occupied.
- 4. Rent, Communication and Utilities: ICDDR,8 transport will be used.
- 5. Collaborative arrangement with Dhaka Shishu Hospital.

Abstract Summary for Ethical Review Committee

- The project aims at caring for the most vulnerable children of persistent diarrhoea through defined measures and the investigations will be directly useful to formulate appropriate dietary regimes.
 - Children less than 2 years are most vulnerable and will receive standard care at hospital. The investigations will not cause any risk to the child.
- Informed consent will be obtained from parents or legal guardian of each child. They will be identified by code number to ensure confidentiality.
- There maybe immediate benefit that persistent diarrhoea in young children will be treated with knowledge of investigations and ICDDR, B general hospital service cannot provide every detailed investigations. The cases will have all necessary dietary intervention and treatment of pathogens.
- 4. The samples required for investigations are 4 ml blood for Dxylose and routine examination. Stool and urine will be collected as required.
- There will be record of the patients for use in the study. No other record will be necessary.

REFERENCES

Alleyene GAO, Hay RW, Picou DI, Stanfield JP, Whitehead RG. The pathology of protein energy malnutrition. Edward Ernold. London.1977;pp 244-245.

Ansari Z, Malík AS, Dutta AK, Ahmed SH and Saiahuddin. Prevalence of sugar intolerance in diarrhoea of infancy and childhood. Indian Pediat.

Avery 6B, Villavicencio L, Lilly JR, Randolph JG. Intractable diarrhoea in early infancy. Pediatrics. 1968;41:712-722

Balistreri MF. Bile acid induced intestinal dysfunction: implications to protracted infantile diarrhoea and malnutrition. In: Chronic diarrhoea in children. ed. Labenthal E. Nestle, Raven press. New york, 1984; pp: 347-364,

Bari A. Chandpur project, ICDDR, B (Personal communication) 1986

Behrens R, Docherty H, Elia M, Neale G. A simple enzymatic method for the assay of urine lactulose. Clin Chem. Acta. 1983;137; 361-367.

Black RE, Brown KH, Becher A, Alim ARMA, Huq I. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. AM J Epid. 1982;115:315-324,

Chandra RK, Pawa RR, Ghai OP. Sugar intolerance in malnourished infants and children. Brit Med J. 1968;4:611-613

Davidson GP, Robb TA. Children with chronic diarrhoea and altered disaccharidase ratio who respond to sucrose withdrawal. Lancet 1982; 2:325,

Ford RPK, Menzies IS, Phillips Ad, Walker-Smith JA, Turner M. Intestinal sugar permeability: Relationship to diarrhoeal disease. J Ped Gastroenterol Nutr.1985;7:468-474.

Gordon JE. Diarrheal disease of early childhood ~ worldwide sign of the problem. Ann N.Y. Acad Sci. 1971;176:9-15.

Gordon JE. Nutrition and infection field study in guatemalan villages. Arch Environ Hlth.1968;16:423-437.

Gracey M, Burke V, Anderson CM. Association of monosaccharide malabsorption with abnormal intestinal flora. Lancet 1969; 2,384.

Gracey M, Stone DE. Small intestinal microflora in Australian aboriginal children with chronic diarrhoea. Aust N Zeal J Med. 1972;3:215-219.

Halliday K, Edmeades R, Shepherd R. Persistant postenterilities diarrhoea in childhood. Med J Aus. 1982;1:18-20.

Henry RJ. Clinical Chemistry: Principles and Technics. Harper and Two. New York, 1964 Jackson D, Walker-Smith JA, Phillips AD. Macromolecular absorption' by histologically normal and abnormal small intestinal mucosa in childhood: An invitro study using organ culture. J Ped Gastroenterol Nutr.1983;2:235-248.

Jain MK, Bhui PS, Menta NJ, Taskar SP, Sane SY, Menta AP. The role of pancreas: Pancreatic function in malnourished children. In Walker-Smith JA and McNeish AS eds. Diarrhoea and malnutrition in childhood. Butterworths, London, Boston, Sydney. 1986;142-146.

Jalili F, O'Brian Smith E, Nichols VN, Mintz AA, Nichols B. Comparison of acquired monosaccharide intolerance and acute diarrheal syndrome. J Ped Gastro & Nutr. 1982;1:81-89.

Kilby AM, Dolby JM, Honour P, Walkersmith JA. Duodenal bacterial flora in early stages of transient monosaccharide intolerance in infants. Arch Div Childhood. 1977:52:228.

Larchar VF, Shepherd R, Francis DEM, Harries JT. Protracted diarrhea in infancy. Analysis of 82 cases with particular reference to diagnosis and management. Arch Dis Child. 1977;52:597-605.

Lifshitz F, Coello-Ramirez P, Gutierrez-TopeteG, Gutierrez MLC. Monosaccharide intolerance and hypoglycemia in infants with diarrhea. I. Clinical course of 23 infants. J Peds.1970;77:595-603.

Lui H, Tsao MU, Morre B, Giday Z. Bovine milk protein-induced intestinal malabsorption of lactose and fat in infants. Gastroenterology.1968;54:27-34

Mata LJ, Kronmal RA, Garcia B, Butler W, Urrutia JJ, Murillo S. Breast-feeding, weaning and the diarrheal syndrome in a Guatemalan Indian village. In: Acute Diarrhea in Childhood. Ciba Foundation Symposium 42 (new series) June. 1976, Elsevier/North Holland.

Mehta AP, Doiphode Sh, Dhar AP, Jain MK. Bacterial overgrowth in the small intestine in malnourished children. In Walker-Smith JA and McNeish AS eds. Diarrhoea and malnutrition in childhood. Butterworths, London, Boston, Sydney.1986;43-49.

Merson MH, Director. Diarrhoeal Disease Control Programme, WHO, Geneva (personal Communication) 1986.

Molla A, Molla AM, Rahim A, Sarker SA, Mozaffar I, Rahaman M. Intake and absorption of nutrients in children with cholera and rotavirus infection during acute diarrhoea and after recovery. Nutr Res. 1982; 2, 233-242.

Perez Flores CA. Diarrhea cronica infantil. Doctoral Thesis, Universidad Peruana Cayetano Heredia, Lima, Peru, 1972

Rahaman MM, Aziz KMS, Rahman M, Alam N. Do replated attacks of acute diarrhoea cause chronic diarrhoea? In Walkersmith JA and McNeish AS, ed. Diarrhoea and Malnutrition in Childhood. Butterworths, London, Boston, Durban, Singapore, Toronto, Wellington. 1986;PP 103-106.

Roe JH, and Rice EW. Photomatic method of determination of free pentoses in animal tissues. J Biol Chem. 1948;173;507-512.

Sack DA, Rhoads M, Molla A, Molla AM, Wahed MA. Carbohydrate malabsorption in infants with rotavirus diarrhoea. Am J Clin Nutr. 1982;36: 1112-1118.

Sack RB. Chronic Diarhoea of children living in the developing world: A review. WHO, Geneva, 1983

Sarker SA, Molla AM, Karim AKMM, Rahaman MM. Calorie intake in childhood diarrhea. International Centre for Diarrhoeal Disease Research, Bangladesh, Scientific Report 57, Dhaka, Bangladesh, July 1982

Snyder JD and Merson MH. The magnitude of the global problem of acute diarrhoea disease: a review of active surveillance data. Bull WHO. 1982;60:605-613.

Van de Kamer JH, Ten Bokkel Huinik H, and Weyers HA. Rapid method of determination of fat in feces. J Biol Chem. 1949;12;177-507.

Walkersmith JA, Harrison M, Kilby A, Phillips A, and Francee NE. Cows milk sensitive enteropathy. Arch Dis Childhood. 1978;53:375-380.

Whitington PE, Gibson R, Soyprotein intolerance, four patients with concomitant cow's milk intolerance. Pediatrics. 1977;59:730-732.

Yamanaka K. D-Mannitol dehydrotgenase from leukonostocmesente-roides. In. W. Wood ed. Methods in enzymology, Academic Press, New York, XL1 part 8,1975; P 138-142.

BUDGET

Personnel					
у айв	Fēñēj Wo:	$ar{\chi}$	Time(month)	Rate/m'	Annual US\$
Dr. S.K. Roy	NO-B	25	12	470	1,410
Dr. A.N. Alam	P-3	-	-	-	-
Dr. R. Haider	NO-A	25	12	360	1,320
Mrs. N. Majid (Dietation)	GS VI	25	12	300	300
Dr. F.C. Patra	**	-	_	. -	-
Prof. M.S. Akbar	-	-	-	-	-
Physician	NO-A	100	12	250	3,000
Research Officer	GS-V	50	12	200	1,200
Study Clerk	GS-IV	75	12	190	1,710
Secretary	GS-V	. 25	. 12	200	600
·					10,140
	•				
Supplies and mate	rials			•	
Glass ware			_	 *-	250
Hospital supply	<i>f</i>				200
Stationery and	office supp	al y			300
Chemicals and a	nedia				300
Laboratory supp	nly		•		500
Non-stock suppl	lies	•			500
	•				2,350
Rent, communica	ation, utili	ities			1,000
Printing and p	ublication				500

<u>Interdepartmental</u> services:

Computer (Programmer	1 for 2 months	1,000
Xerox	,	300
Pathology: Stool M.E.		200
Urine R.E.		200
CBC		200
Microbiology: Stool C.S., LT, ST		500
ELISA		350
Campylobacter		450
Blood culture		500
Biochemistry: Fat estimation .		750
Protein estimation		200
Carbohydrate (TLC)		100
Energy		200
Blood electrolyte		400
D-xylose test		500
X-ray	•	100
Patient hospitalization		10,000
Maintenance charges		1,000
	Sub	Total : 18,850

<u>Budget Summary</u>

Personnel	\$10,140	(Conversion rate US\$1=Taka30)
Supplies	\$ 2,050	•
Other	\$ 1,500	
Interdepartment	\$18,850	
	\$32.540	

(Total Direct Cost = US\$:33,760)

ICDDR, B CONSENT FORM

(Mechanism of nutrient absorption in persistent diarrhoea)

(Will be read and explained clearly before consent is obtained.)

Your child is suffering from a diarrhoea which usually takes longer period for recovery. In fact there are deficit in knowledge about malabsorption of dietary nutrients in this type of disease.

We are undertaking a study to know this problem more clearly by which better management may be outlined. This study will most likely help your child for earlier recovery and then will be helpful for many other children. There is no risk in this study.

If you agree to put your child in this study, the following steps will be applicable to him/her.

- He/she will be kept in Metabolic ward and stool, urine vomitus will be collected.
- 2. An amount of 4 ml blood will be obtained during the study.
- Your child will be given two harmless tablet and stool collection for 48 hours will be required.
- Small amount of Sugar solution will be fed and will be examined from urine.
- 5. He/she will receive intravenus solution as and when required.
- We shall examine his/her health at hospital regularly.

You will always be at liberty to withdraw from study yet the child will receive treatment in this hospital.

Signature of the Principal
Investigator

Signature of the guardian/ left thumb impression

APPENDIX I

Procedure for D-xylose test

This test will be done within 48 hours of balance study by 4 hours fasting followed by feeding 5 gram D-xylose dissolved in 100 ml of water. After one hour of drinking D-xylose solution, 0.5 ml of venous blood will be drawn for estimation of serum xylose level (Roe JH et al., 1948).

APPENDIX II

Procedure for permeability test

Under supervision of investigator, infants will be given a freshly prepared drink containing 5g lactulose with 0.5g lactose (7.5 ml Duphalac, Duphar Ldd., Southampton, UK) and 1g mannitol in 20 ml 1% Chloroform water. Breast feeding and fluid intake will be encourraged during the test. Urine samples will be collected for 5 hours into adhesive uribags. One drop of 20% v/v chlorhexidine gluconate will be added to each urine collection. Urine volume will be measured and recorded. Aliquots (5 ml) will be taken and stored at -20 C. Lactulose and lactose can be measured using an automated enzyme assay system (Behrons R. 1983). Mannitol can be assayed by using a similar assay based on the oxidation of the sugar by mannitol dehydrogenase prepared from Leuconostomesenteriodes (y amanaka K. 1975).

(अभीक पडमां र्यात् वाका सा इद्ध) मुस्लांजु शर्मांबंगारी जामे येद्र अधुक्रा (काउँ (मर्काकांष)

क्ष्मिक, अस् । द्वाकि अम्मानं मुम्मक्षेत्र काल स्मान स्मान प्रमान कार्या कार्य

त्राक्ष्याव- नुमाळ्ख- जार्थामा सर्व- अन्न अर्द्ध- भवः ज्य नुम्भाउ- नुमाळ्ख- त्राम अद- टाबिम्नम्म जर्नेहिक क्ष्य

भाव। अभ भीने, याम अयुक्ति क्यांक्ष्य क्षेत्रिस अवह आखारमीय अभ भीने, याम अयुक्ति क्यांक्ष्य ह त्यांत्रिय ह

इत्र ३ मी. अधुकार क्या इंद्रिय । ह। अक क्षेत्राव- त्रिश्चिव अवववह (०० शि: थि:) माउजासा

ज्ञात्रावं ज्ञालाक्त्य तत्रवंगा वद्गद्य। व। व्यव्यं ज्ञाल्यक्त ज्ञीत्र्यक्षिणक् श्रेमी मुक्रावाक् क्ष्मी. वा

नति रुपत्र । का न्यानक कार्यावे प्रिक्ष अधिकार कर्षिया देशमेश रिक्रिशंखा अपृक्षत् । ठ्यास्त्रीय कृषित्य कार्यावे स्थाळिक अप्राप्त अर्थे स्थित्रम्यं ठ्यास्त्रीय द्रव्या कृषित्य लाक्ष्मावं तृत्राक्यक अर्थे सब्ग्रिक्य १। ल्यास्त्रमण्डे- तृत्राक्षवं- माववं- लामीत्य स्थामात्म अत्रत्व- भा।

अक्षान राजिम् एवं नाम्य

অহিত্যক্তর নীম্যার-/ধ্যমমত্র

ত্রপরস

ZINC SUPPLEMENTATION IN DIARRHOEA

APPENDIX I	<u>rv</u>	Date:	
(MOREIDITY)	ļ	Patient No.:	

	Туре	Duration	Severity	Treatment
1.	Diarrhœa			
2.	Dysentery (Blood)	·		
3.	Mucoid			
4.	RTI			
5.	Fever			
6.	Measles	·		
7.	Skin infection			
8.	Cough			
9.	Mumps		·	
10.	Chichen pox			
11.	Ear infection			
12.	Oral thrus			
13.	Cral sore			
14.	Other	;		